VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Termination of a Material Definitive Agreement

VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Termination of a Material Definitive Agreement
ITEM 1.02

TERMINATION OF A MATERIAL DEFINITIVE AGREEMENTS

Effective June 1, 2017 the previously announced Memorandum of Understanding (“MOU”) between Vitro Diagnostics, Inc. (the “Company”) and Caribbean GC Development Fund, Ltd., a Grand Cayman corporation (“Caribbean GC”) has been terminated without consummation.

The Company has no plans to further pursue the matter.


About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Recent Trading Information

VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) closed its last trading session up +0.028 at 0.106 with 2,000 shares trading hands.

An ad to help with our costs